LTRN supply chain intelligence for Lantern Pharma Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Lantern Pharma Inc. (LTRN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BERKSHIRE-STERILE-MANUFACTURING | BERKSHIRE-STERILE-MANUFACTURING | 92% | We have contracted with Berkshire Sterile Manufacturing for the provision of services relating to cGMP drug product manufacturing of LP-300. |
| CURIA-GLOBAL-INC | CURIA-GLOBAL-INC | 92% | We have contracted with Curia Global, Inc. for the manufacture and supply of LP-300 cGMP API material. |
| PIRAMAL-PHARMA-SOLUTIONS | PIRAMAL-PHARMA-SOLUTIONS | 92% | We have contracted with Piramal Pharma Solutions for the provision of services relating to cGMP drug product manufacturing of LP-300. |
| SHILPA-MEDICARE-LIMITED | SHILPA-MEDICARE-LIMITED | 92% | We have contracted with Shilpa Medicare Limited and affiliates for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug product manufacturing of LP-184. |
| ACTUATE-THERAPEUTICS | ACTUATE-THERAPEUTICS | 90% | The Company and Actuate have collaborated on utilization of the Company’s RADR ® platform to develop novel biomarker derived signatures for use with one of Actuate’s product candidates. |
| BIONUMERIK-PHARMACEUTICALS-INC | BIONUMERIK-PHARMACEUTICALS-INC | 90% | LP-300 is a small molecule that was in-licensed from BioNumerik Pharmaceuticals, Inc. in May 2016, and subsequently acquired by us in 2018. |
| SIEGFRIED-ACCELERATION-HUB | SIEGFRIED-ACCELERATION-HUB | 90% | In 2025, the Curia site where the LP-300 API is manufactured changed its name to Siegfried Acceleration Hub, reflecting the acquisition of the manufacturing site by the Siegfried Group. |
| THINKEQUITY-LLC | THINKEQUITY-LLC | 90% | On May 12, 2026, the Company suspended offers and sales of the shares of Common Stock pursuant to the prospectus supplement, dated July 3, 2025, relating to the ATM Sales Agreement, dated July 3, 202… |
| ACTUATE-THERAPEUTICS-INC | ACTUATE-THERAPEUTICS-INC | 85% | Pursuant to the agreement, we collaborated on utilization of our RADR ® platform to develop novel biomarker derived signatures for use with one of Actuate's product candidates. |
| BIELEFELD-UNIVERSITY | BIELEFELD-UNIVERSITY | 85% | In 2023, we entered into a research collaboration with Bielefeld University in Germany focused on development of ADCs utilizing cryptophycin as the ADC drug-payload. |
| TTC-ONCOLOGY | TTC-ONCOLOGY | 85% | In February 2023, we entered into a Collaboration Agreement with TTC Oncology. |
| ZETA-AI | ZETA-AI | 80% | plans to create an independent business entity composed of the AI platform, with Zeta.ai, and related technologies and personnel under the leadership of CEO Mr. Panna Sharma |
| JNJ | Johnson & Johnson | 72% | the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PCT patent application filed in 2020 is dir… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four fam… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLARITY-THERAPEUTICS-A-S | ALLARITY-THERAPEUTICS-A-S | 90% | LP-100 was previously out-licensed by us to Allarity Therapeutics A/S. |
| TRIVIUMVET-DAC | TRIVIUMVET-DAC | 90% | We will provide TriviumVet DAC with (i) specified data and information generated by us with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark r… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PCT patent application filed in 2020 is dir… |
| AF-CHEMICALS-LLC | AF-CHEMICALS-LLC | 62% | o retain and motivate our current personnel, our business and future growth prospects could be severely harmed. 87 Our employees may engage in misconduct or other improper activities, including nonco… |
| LP-184-CHEMICAL-STRUCTURE-STARLIGHT-THERAPEUTICS | LP-184-CHEMICAL-STRUCTURE-STARLIGHT-THERAPEUTICS | 62% | we are required to pay the BioNumerik-related payment recipients a specified percentage of any upfront, milestone, and royalty amounts received by us from the transaction, after first recovering spec… |
| PRESENTATION-LANTERN-PHARMA-INC | PRESENTATION-LANTERN-PHARMA-INC | 62% | rial expenses based on the information available to the Company at that time. The estimation of accrued research and development expenses was also identified as a critical accounting estimate by mana… |
| RESTATED-LANTERN-PHARMA-INC | RESTATED-LANTERN-PHARMA-INC | 62% | Present value of future minimum lease payments 78,539 Less current portion of operating lease liabilities ( 78,539 ) Operating lease liabilities, net of current portion $ - At December 31, 2025, the … |
| STARLIGHT-THERAPEUTICS-INC | STARLIGHT-THERAPEUTICS-INC | 62% | we are required to pay the BioNumerik-related payment recipients a specified percentage of any upfront, milestone, and royalty amounts received by us from the transaction, after first recovering spec… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LTRN-DEBT | Debt stack $59,076 | 90% | Market cache reports total debt of $59,076. |
| LTRN-DEBT-10812 | Warrants outstanding: 86685 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LTRN-OWNER-BIOS-CAPITAL-MANAGEMENT-LP | BIOS Capital Management, LP | 90% | 13F overlay lists BIOS Capital Management, LP as top holder; 32 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| ANIK | Anika Therapeutics, Inc. | 50.00 | 2 | |
| DYAI | Dyadic International, Inc. | 50.00 | 2 | |
| AORT | Artivion, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| ENGNW | enGene Therapeutics Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 | |
| FCX | Freeport-McMoRan Inc. | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 50.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 50.00 | 2 | |
| AVTX | Avalo Therapeutics, Inc. | 50.00 | 2 | |
| CSTE | Caesarstone Ltd. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| CVRX | CVRx, Inc. | 50.00 | 2 | |
| SNNUF | Smith & Nephew plc | 50.00 | 2 | |
| ALC | Alcon Inc. | 50.00 | 2 | |
| ATNM | Actinium Pharmaceuticals, Inc. | 50.00 | 2 | |
| BLLN | BillionToOne, Inc. | 50.00 | 2 |